Market closedNon-fractional
MannKind/MNKD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
MNKD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Danbury, United States
Employees
413
Website
www.mannkindcorp.com
MannKind Metrics
BasicAdvanced
$1.6B
Market cap
183.57
P/E ratio
$0.03
EPS
1.34
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
1.34
Financial strength
Current ratio
3.835
Quick ratio
3.285
Long term debt to equity
-148.715
Total debt to equity
-161.705
Interest coverage (TTM)
1.06%
Management effectiveness
Return on assets (TTM)
4.97%
Return on equity (TTM)
-3.50%
Valuation
Price to earnings (TTM)
183.573
Price to revenue (TTM)
6.937
Price to book
-6.84
Price to tangible book (TTM)
-6.75
Price to free cash flow (TTM)
502.078
Growth
Revenue change (TTM)
74.92%
Earnings per share change (TTM)
-111.42%
3-year revenue growth (CAGR)
50.15%
3-year earnings per share growth (CAGR)
-50.67%
What the Analysts think about MannKind
Analyst Ratings
Majority rating from 6 analysts.
MannKind Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$66M
13.36%
Net income
$11M
657.14%
Profit margin
16.01%
569.87%
MannKind Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.02
$0.01
-
$0.04
-
Expected
-$0.04
-$0.02
$0.00
$0.03
$0.01
Surprise
-47.37%
-160.61%
-
53.85%
-
MannKind News
AllArticlesVideos
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions
GlobeNewsWire·1 month ago
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
GlobeNewsWire·2 months ago
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.6B as of July 27, 2024.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 183.57 as of July 27, 2024.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell MannKind stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.